companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2019
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 5,751,063 and a net result of DKK 1,316,612. Equity amounted to DKK 3,148,590. The solvency ratio was 13%. The company had 10 employees in the financial year.
- Gross Profit
- 5,751,063 kr.
- Profit/Loss
- 1,316,612 kr.
- Equity
- 3,148,590 kr.
- Total Assets
- 24,239,019 kr.
- Employees
- 10
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
As of November 28, 2019, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
As of November 28, 2019, BDO Holding VII, statsautoriseret revisionsaktieselskab has stepped down as auditor of Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.